Department of Psychiatry, School of Medicine, University of Kocaeli, Derince, Kocaeli, Turkey.
Int J Psychiatry Clin Pract. 2004;8(1):41-5. doi: 10.1080/13651500310003327.
Pharmacotherapy for schizophrenia is a dynamic process that can change over time. The goal of this study was to examine the pattern of antipsychotic drug (APD) use for patients with schizophrenia in an outpatient clinic.
We evaluated the medication use pattern in patients with schizophrenia treated with antipsychotic drugs in an outpatient clinic in a period of 4 years. Patients who used any antipsychotic medication stably for at least 6 months were included in the study in this period. Patients who had been noncompliant to the treatment or did not come to the clinic again were excluded. Patients' records were reviewed in respect to the use of APD as an initial treatment, the duration of a single or combined APD use, the changing of APD regimen, and adding of a new APD or other adjuvant drugs to APDs.
A total of 152 patients diagnosed with schizophrenia were treated during the study period, of whom 60 (39.5%) maintained the treatment with compliance for at least 6 months. Mean duration of the treatment was 15.8 (+10.7) months (range 6-48). The most commonly used antipsychotic drugs were atypical agents (in 68.3% of patients), and depot neuroleptics were used in the 46.7% of patients more often than any other antipsychotic drug at any time of the treatment. Two or more antipsychotic drugs were used at some time during this period in 24 patients (40.0%). Of all patients, 45.0% had their drug regimen changed: medication regimen was changed once in 28.3% patients and two to four times in 16.7% patients. The longer the duration of treatment, the more patients had their medication changed. Most added drugs were typical ones (16.7%). Of all patients, 48 (80.0%) had used adjuvant drugs at any time during the treatment. There were no differences between the use of combined drug, medication changing and demographic variables of the patients.
The results of this study support previous reports of the frequent use of atypical antipsychotic drugs, combination antipsychotic therapy, and adjuvant drugs in clinical practice. Medication switching is more common in the treatment of patients with schizophrenia. Prospective controlled trials are needed to determine whether combination antipsychotic therapy or switching medication regimen is clinically beneficial and to provide guidelines on when and for whom that should be considered. (Int J Psych Clin Pract 2004; 8: 41-45).
精神分裂症的药物治疗是一个动态的过程,可能会随时间而改变。本研究的目的是考察门诊精神分裂症患者抗精神病药物(APD)使用模式。
我们评估了 4 年内门诊使用抗精神病药物治疗的精神分裂症患者的药物使用模式。在这段时间内,使用任何抗精神病药物稳定治疗至少 6 个月的患者被纳入研究。不遵守治疗或不再来诊所的患者被排除在外。对患者的记录进行了回顾,内容包括作为初始治疗的 APD 使用、单一或联合 APD 使用的持续时间、APD 方案的改变、以及向 APD 添加新的 APD 或其他辅助药物。
在研究期间,共有 152 名诊断为精神分裂症的患者接受了治疗,其中 60 名(39.5%)至少维持了 6 个月的治疗。治疗的平均持续时间为 15.8(+10.7)个月(范围 6-48)。最常使用的抗精神病药物是非典型药物(68.3%的患者),在治疗的任何时候,长效神经阻滞剂的使用频率都高于任何其他抗精神病药物(46.7%的患者)。在此期间,有 24 名患者(40.0%)在某些时候使用了两种或更多种抗精神病药物。所有患者中,45.0%的患者改变了药物治疗方案:28.3%的患者改变了一次治疗方案,16.7%的患者改变了两到四次治疗方案。治疗时间越长,改变药物治疗方案的患者越多。最常添加的药物是典型药物(16.7%)。所有患者中,48 名(80.0%)在治疗过程中的任何时候都使用了辅助药物。联合用药、药物更换与患者人口统计学变量之间无差异。
本研究结果支持以前的报告,即临床实践中经常使用非典型抗精神病药物、联合抗精神病治疗和辅助药物。在精神分裂症患者的治疗中,药物转换更为常见。需要进行前瞻性对照试验,以确定联合抗精神病治疗或改变药物治疗方案是否具有临床益处,并为何时以及为谁考虑这些方案提供指导。(国际精神病学临床实践 2004;8:41-45)。